Gossamer Bio, Inc. (GOSS)
Automate Your Wheel Strategy on GOSS
With Tiblio's Option Bot, you can configure your own wheel strategy including GOSS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: April 03, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, April 03, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Gossamer Bio, Inc. (“Gossamer” or “the Company”) (NASDAQ: GOSS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between June 16, 2025 and February 20, 2026, inclusive (the “Class Period”), are encouraged to contact the firm before June 1, 2026.
Read More
GOSS INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026
Published: April 03, 2026 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Gossamer To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Gossamer between June 16, 2025 and February 20, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, April 3, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Gossamer Bio, Inc. ("Gossamer" or the "Company") …
Read More
Berger Montague PC Investigating Claims on Behalf of Gossamer Bio, Inc. (GOSS) Investors After Class Action Filing
Published: April 03, 2026 by: Newsfile Corp
Sentiment: Neutral
Philadelphia, Pennsylvania--(Newsfile Corp. - April 3, 2026) - National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer" or the "Company") on behalf of investors who purchased or acquired Gossamer shares during the period from June 16, 2025 through February 20, 2026 (the "Class Period"). Investor Deadline: Investors who purchased or acquired Gossamer securities during the Class Period may, no later than June 1, 2026, seek to be appointed as a lead plaintiff representative of the class.
Read More
Bronstein, Gewirtz & Grossman LLC Urges Gossamer Bio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Published: April 02, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, April 02, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Gossamer securities between June 16, 2025 and February 20, 2026, both dates inclusive (the “Class Period”).
Read More
Investor Notice: Robbins LLP Informs Investors of the Gossamer Bio, Inc. Class Action Lawsuit
Published: April 01, 2026 by: Business Wire
Sentiment: Neutral
SAN DIEGO--(BUSINESS WIRE)---- $GOSS #Health--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Gossamer Bio, Inc. (NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026. Gossamer is a clinical stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension (PH) associated with interstitial lung disease. For more information, submit a form, email a.
Read More
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Gossamer Bio, Inc. (GOSS)
Published: April 01, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, April 01, 2026 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of California on behalf of all persons or entities who purchased or otherwise acquired Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS) securities between June 16, 2025, and February 20, 2026, inclusive (the “Class Period”).
Read More
GOSS DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026
Published: April 01, 2026 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Gossamer To Contact Him Directly To Discuss Their Options
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
Published: March 19, 2026 by: PRNewsWire
Sentiment: Neutral
NEW YORK, March 19, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Earnings Preview: Gossamer Bio (GOSS) Q4 Earnings Expected to Decline
Published: March 05, 2026 by: Zacks Investment Research
Sentiment: Negative
Gossamer Bio (GOSS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Investigation Alert: Levi & Korsinsky Investigates Securities Fraud Claims Against Gossamer Bio, Inc. (GOSS)
Published: March 03, 2026 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - March 3, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Gossamer Bio, Inc. ("Gossamer Bio, Inc.") (NASDAQ: GOSS) concerning potential violations of the federal securities laws. Seralutinib was Gossamer Bio's lead pipeline candidate and the PROSERA study was the Company's pivotal Phase 3 trial evaluating the drug in pulmonary arterial hypertension.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
Published: February 26, 2026 by: PRNewsWire
Sentiment: Neutral
NEW YORK, Feb. 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Here's Why Gossamer Bio (GOSS) Is a Great 'Buy the Bottom' Stock Now
Published: February 26, 2026 by: Zacks Investment Research
Sentiment: Positive
Gossamer Bio (GOSS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Read More
Gossamer Bio (GOSS) Loses 85% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Published: February 26, 2026 by: Zacks Investment Research
Sentiment: Negative
Gossamer Bio (GOSS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Read More
Gossamer Bio's experimental lung condition drug fails in late-stage trial
Published: February 23, 2026 by: Reuters
Sentiment: Negative
Gossamer Bio said on Monday its experimental drug missed the main goal of a late-stage study in patients with a serious lung and heart condition.
Read More
Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension
Published: February 23, 2026 by: Business Wire
Sentiment: Neutral
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS) a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced topline results for the PROSERA Phase 3 Study of seralutinib in patients with PAH. Gossamer Bio and the Chiesi Group are jointly developing seralutinib under a global collaboration agreement.
Read More
Gossamer Bio: Bullish Ahead Of Seralutinib's Phase 3 Readout
Published: September 09, 2025 by: Seeking Alpha
Sentiment: Positive
GOSS's Seralutinib remains its main value driver. This is an inhaled TKI for PAH and PH-ILD. Seralutinib's PROSERA Phase 3 trial is now fully enrolled with 6MWD as its primary endpoint. We should get its topline data by February 2026. As for Seralutinib's PH-ILD indication, the SERANATA Phase 3 trial will begin site activations in Q4 2025.
Read More
Gossamer Bio, Inc. (GOSS) Q1 2025 Earnings Conference Call Transcript
Published: May 15, 2025 by: Seeking Alpha
Sentiment: Neutral
Gossamer Bio, Inc. (NASDAQ:GOSS ) Q1 2025 Earnings Conference Call May 15, 2025 4:30 PM ET Company Participants Bryan Giraudo - COO & CFO Faheem Hasnain - Co-Founder, CEO, President & Chairman Richard Aranda - Chief Medical Officer Caryn Peterson - EVP, Regulatory Affairs Bob Smith - Chief Commercial Officer Conference Call Participants Joseph Schwartz - SVB Leerink Andreas Argyrides - Oppenheimer Yasmeen Rahimi - Piper Sandler & Co. Paul Choi - Goldman Sachs Olivia Brayer - Cantor Patrick Trucchio - HC Wainwright Laura Chico - Wedbush Operator Good afternoon, ladies and gentlemen, and welcome to the Gossamer Bio Q1 …
Read More
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Published: May 07, 2025 by: Business Wire
Sentiment: Neutral
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective May 5, 2025, to three non-executive employees of non-qualified stock optio.
Read More
Gossamer Bio Is A Good Speculative Buy On Seralutinib For PAH And PH-ILD
Published: February 13, 2025 by: Seeking Alpha
Sentiment: Neutral
Gossamer Bio develops Seralutinib, which is basically an inhaled TKI that targets vascular remodeling, inflammation, and fibrosis. This makes it ideal for treating PAH and PH-ILD. GOSS has so far produced encouraging Phase 2 data and has an ongoing Phase 3 PROSERA trial for PAH. The main event comes with its topline results in Q4 2025. GOSS's pipeline includes a PH-ILD program slated to start Phase 3 in mid-2025. This program addresses a larger, high-mortality TAM.
Read More
About Gossamer Bio, Inc. (GOSS)
- IPO Date 2019-02-08
- Website https://www.gossamerbio.com
- Industry Biotechnology
- CEO Faheem Hasnain
- Employees 144